Collectively, we show that CALR variants are genuine ERAD substrates and propose that modulations of ERAD activity could represent a therapeutic target for CALR-mutated MPN patients to attenuate CALR variant-dependent MPL activation. Here, MPL is linked to myeloproliferative neoplasm.